Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

ClinicalTrials.gov ID: NCT05368428

Public ClinicalTrials.gov record NCT05368428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Single-Institution Trial Investigating the Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) in Taxane Induced Peripheral Neuropathy (CIPN) in Patients With Early Stage Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial examines transcutaneous electrical nerve stimulation (TENS) in patients with stage I-III breast cancer with chemotherapy induced peripheral neuropathy. TENS is a procedure in which mild electric currents are applied to some areas of the skin to potentially improve neuropathy. This trial may help determine if TENS is feasible and effective for the treatment of peripheral neuropathy symptoms while on chemotherapy.

Study identification

NCT ID: NCT05368428
Recruitment status: Terminated
Study type: Interventional
Phase: Not applicable
Lead sponsor: Emory University; Other
Enrollment: 17 participants

Conditions and interventions

Conditions

Interventions

Transcutaneous Electrical Nerve Stimulation Other

Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 18, 2022
Primary completion: Nov 17, 2025
Completion: Nov 17, 2025
Last update posted: May 17, 2026

2022 – 2025

United States locations

U.S. sites: 3
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Emory University Hospital Midtown	Atlanta	Georgia	30308	—
Emory University/Winship Cancer Institute	Atlanta	Georgia	30322	—
Emory Saint Joseph's Hospital	Atlanta	Georgia	30342	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05368428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 17, 2026 · Synced Sep 11, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05368428 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →